|MDACC Study No:||2012-0062 (clinicaltrials.gov NCT No: NCT01546038)|
|Title:||A Phase 1B/2 Study to Evaluate the Safety and Efficacy of PF-04449913, an Oral Hedgehog Inhibitor, in Combination with Intensive Chemotherapy, Low Dose Ara-C or Decitabine in Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome|
|Principal Investigator:||Jorge Cortes|
|Treatment Agent:||Cytarabine; Daunorubicin; PF-04449913|
|Study Description:||The goal of Part 1 of this clinical research study is to learn the highest |
tolerable dose of PF-04449913 that can be given with cytarabine or decitabine
to patients with AML or high-risk MDS. The goal of Part 2 (Expansion) is to
learn if the study drug combinations can help to control the disease.
PF-04449913 is designed to stop the growth of certain cancer stem cells that
may allow cancer to grow.
Cytarabine is designed to insert itself into DNA (genetic material) of cancer
cells and stop the DNA from repairing itself.
Decitabine is designed to damage the DNA of cells, which may cause cancer cells